RESEARCH ARTICLE

The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study [version 1; peer review: 2 approved]

Malcolm A. West¹⁻³, Zachos Anastasiou⁴, Gareth Ambler⁴, Lisa Loughney^{id 2,3}, Michael G. Mythen⁵, Thomas Owen⁶, Gerard Danjoux⁷, Denny Z.H. Levett^{2,3}, Peter M.A. Calverley⁸, Jamie J. Kelly⁹, Sandy Jack^{2,3}, Michael P.W. Grocott^{2,3}, Fit4Surgery Consortium

¹Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK

²Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, SO16 6YD, UK

³Acute Perioperative and Critical Care Research Group, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK

⁴Department of Statistical Science, University College London, London, W1T 7PJ, UK

⁵Centre for Anaesthesia, Institute of Sport Exercise and Health, University College London Hospitals NIHR Biomedical Research Centre, London, W1T 7HA, UK

⁶Department of Critical Care and Anaesthesia, Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, PR7 1PP, UK

⁷Department of Critical Care and Anaesthesia, The James Cook University Hospital, Middlesbrough, TS4 3BW, UK

⁸Department of Respiratory Research, University of Liverpool, University Hospitals Aintree, Liverpool, L9 7AL, UK

⁹Department of Upper Gastro-intestinal Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, SO16 6YD, UK

V1 First published: 16 Jun 2021, 1:1
<https://doi.org/10.3310/nihropenres.13217.1>
 Latest published: 16 Jun 2021, 1:1
<https://doi.org/10.3310/nihropenres.13217.1>

Abstract

Background: Neoadjuvant cancer treatment is associated with improved survival following major oesophagogastric cancer surgery. The impact of neoadjuvant chemo/chemoradiotherapy on physical fitness and operative outcomes is however unclear. This study aims to investigate the impact of neoadjuvant chemo/chemoradiotherapy on fitness and post-operative mortality.

Methods: Patients with oesophagogastric cancer scheduled for chemo/chemoradiotherapy and surgery were recruited to a prospective, blinded, multi-centre, observational cohort study. Primary outcomes were changes in fitness with chemo/chemoradiotherapy, measured using cardiopulmonary exercise testing and its association with mortality one-year after surgery. Patients were followed up for re-admission at 30-days, in-hospital morbidity and quality of life (exploratory outcomes).

Open Peer Review

Approval Status

	1	2
version 1
16 Jun 2021	view	view
1. Javed Sultan , Salford Royal Foundation Trust, Salford, UK		
Patrick Casey , University of Manchester, Manchester, UK		
2. Juliette Hussey , Trinity College Dublin, Dublin, Ireland		

Results: In total, 384 patients were screened, 217 met the inclusion criteria, 160 consented and 159 were included (72% male, mean age 65 years). A total of 132 patients (83%) underwent chemo/chemoradiotherapy, 109 (71%) underwent chemo/chemoradiotherapy and two exercise tests, 100 (63%) completed surgery and follow-up. A significant decline in oxygen uptake at anaerobic threshold and oxygen uptake peak was observed following chemo/chemoradiotherapy: $-1.25\text{ml.kg}^{-1}.\text{min}^{-1}$ (-1.80 to -0.69) and $-3.02\text{ml.kg}^{-1}.\text{min}^{-1}$ (-3.85 to -2.20); $p<0.0001$). Baseline chemo/chemoradiotherapy anaerobic threshold and peak were associated with one-year mortality (HR=0.72, 95%CI 0.59 to 0.88; $p=0.001$ and HR=0.85, 0.76 to 0.95; $p=0.005$). The change in physical fitness was not associated with one-year mortality.

Conclusion: Chemo/chemoradiotherapy prior to oesophagogastric cancer surgery reduced physical fitness. Lower baseline fitness was associated with reduced overall survival at one-year. Careful consideration of fitness prior to chemo/chemoradiotherapy and surgery is urgently needed.

Keywords

O2 diffusion during exercise, Pre-operative evaluation: American College of Cardiology Guidelines

Any reports and responses or comments on the article can be found at the end of the article.

Corresponding author: Michael P.W. Grocott (mike.grocott@soton.ac.uk)

Author roles: **West MA:** Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Anastasiou Z:** Data Curation, Formal Analysis, Writing – Original Draft Preparation; **Ambler G:** Data Curation, Formal Analysis, Writing – Original Draft Preparation, Writing – Review & Editing; **Loughney L:** Data Curation, Formal Analysis, Investigation, Project Administration, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Mythen MG:** Conceptualization, Methodology; **Owen T:** Investigation, Resources; **Danjoux G:** Investigation, Resources; **Levett DZH:** Formal Analysis, Methodology; **Calverley PMA:** Methodology, Resources, Writing – Original Draft Preparation; **Kelly JJ:** Investigation, Resources; **Jack S:** Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing; **Grocott MPW:** Conceptualization, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Supervision, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing;

Competing interests: MAW – National Institute for Health Research funded Academic Clinical Lecturer in surgery at the University of Southampton. ZA, GA, LL, JJK – No external funding and no competing interests declared MGM – Chair at UCL sponsored by Smiths Medical; Consultant for Edwards Lifesciences; Director Medinspire Ltd, UK; Editorial Board Member British Journal of Anaesthesia; Director, Evidence Based Perioperative Medicine Ltd (EBPOM), UK; Director and Editor -in-Chief TopMedTalk; Board member Perioperative Quality Initiative (POQI). TO, GD, DZHL, PMAC, SJ – No external funding and no competing interests declared MG – Joint Editor-in-Chief Perioperative Medicine journal; Director Medinspire Ltd, UK; Director Evidence Based Perioperative Medicine Ltd, UK; Board member, Perioperative Quality Initiative (POQI); Vice President, Royal College of Anaesthetists, UK; Chair National Institute of Academic Anaesthesia, UK; Vice-chair, UK Centre for Perioperative Care.

Grant information: This project is funded by the National Institute for Health Research (NIHR) under its Research for Patient Benefit (RfPB) Programme (Grant Reference Number PB-PG-0609-18262). The views expressed are those of the author(s) and not necessarily those of the NIHR or the Department of Health and Social Care.

Copyright: © 2021 West MA *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: West MA, Anastasiou Z, Ambler G *et al.* **The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: a prospective, blinded, multi-centre, observational, cohort study [version 1; peer review: 2 approved]** NIHR Open Research 2021, 1:1 <https://doi.org/10.3310/nihropenres.13217.1>

First published: 16 Jun 2021, 1:1 <https://doi.org/10.3310/nihropenres.13217.1>

Plain language summary

Background: Cancer treatments such as chemotherapy and radiotherapy given to people with oesophageal and gastric cancer (also known as cancer of the food pipe/stomach) before surgery can improve survival. However, the impact such treatments have on fitness and recovery after surgery is unclear. The aim of this research was to understand the impact cancer treatments has on fitness and any complications after surgery.

Methods: Patients with oesophageal and gastric cancer (also known as cancer of the food pipe/stomach) who were being treated by cancer treatment and surgery were recruited from different hospitals in the UK. All participants were asked to undertake an exercise test to measure fitness and fill out questionnaires to measure quality of life before and after cancer treatment. Complications patients experienced after surgery, the number of patients who had to be readmitted to hospital 30 days after surgery and one-year survival was recorded.

Results: A total of 160 consented to participate in this study and 159 were included in the study (72% male, average age 65 years). In total, 132 patients (83%) had cancer treatment, 109 (71%) had cancer treatment and the two exercise tests and 100 (63%) had surgery and were followed-up after surgery. Study findings show that fitness reduced after cancer treatment. Patient's fitness levels at the start of the study (or before cancer treatment) were linked to one-year survival. The fall in fitness after cancer treatment was not linked to death at the one-year follow-up.

Conclusion: Cancer treatments before oesophageal and gastric cancer reduce fitness. Patients with a lower fitness level before cancer treatment had a reduced overall survival at one-year. Careful consideration of fitness prior to such cancer treatments and surgery is urgently needed.

Introduction

For patients with locally advanced oesophagogastric (OG) cancer, multimodal therapy incorporating surgery and neoadjuvant chemotherapy or combined chemoradiotherapy (referred to as chemo/chemoradiotherapy herein) offers improved survival over surgical therapy alone¹⁻⁴. However, improvement in overall survival may come at the cost of increased treatment toxicity and mortality in some patients^{5,6}.

Physical fitness assessed objectively using Cardiopulmonary Exercise Testing (CPET) may be the best functional predictor of complications following major surgery⁷ and is increasingly being adopted in the perioperative setting to guide perioperative care and decision-making^{8,9}. Preliminary data from our group and others suggest that chemo/chemoradiotherapy before OG cancer surgery result in a clinically important reduction in physical fitness (oxygen uptake (VO_2) at anaerobic threshold (AT) and VO_2 peak)¹⁰⁻¹³. In a small, single-centre, pilot, unblinded study, we previously reported that low baseline physical fitness (VO_2 at AT and VO_2 peak) was associated with reduced one-year survival in patients completing chemotherapy and surgery, but not in patients who did not complete chemotherapy¹⁰.

The aims of this study were to investigate the impact of chemo/chemoradiotherapy on fitness (VO_2 at AT and VO_2 peak), mortality (at one-year after surgery) and post-operative outcomes (Post-Operative Morbidity Survey and EQ-5D-5L). In this prospective, multi-centre, blinded study, we set out to validate the hypothesis that chemo/chemoradiotherapy was associated with reduced physical fitness and that this change in physical fitness (relative change and change in risk stratification category) would be associated with all-cause mortality at one-year. Further, we explored the hypotheses that reduced fitness following chemo/chemoradiotherapy was associated with increased post-operative morbidity and worse patient reported outcomes.

Methods

Study design

This prospective study involved participants with OG cancers scheduled for chemo/chemoradiotherapy followed by elective resection with curative intent. The study protocol, methods and statistical analysis plan are available in open access format¹⁴. This study was funded by the National Institute for Health (NIHR), Research for Patient Benefit Programme (PB-PG-0609-18262). The research protocol was registered with clinicaltrials.gov (NCT01325883 - 30th March 2011) and approved by the Dyfed Powys Research Ethics Committee (11/WA/0072). Written informed consent was obtained from all subjects. The study is described according to the STROBE statement¹⁵.

Recruiting hospitals

The study was conducted in four NHS hospitals in England: University Hospital Southampton (Southampton), University Hospital Aintree (Aintree), Lancashire Teaching Hospital (Preston) and South Tees Hospital (South Tees). A study management board and independent data and safety monitoring committee oversaw the project.

Eligibility criteria

Briefly, patients with a histologically confirmed, potentially curable (able to undergo chemo/chemoradiotherapy followed by curative elective resection) adenocarcinoma, squamous, or mucinous/ undifferentiated carcinoma of the oesophagus, oesophagogastric junction (i.e. tumours involving both the cardia and the oesophagus on endoscopy) or stomach were eligible for inclusion. Eligible patients were ≥ 18 years of age, had a World Health Organization (WHO) performance status score of ≤ 2 , and had adequate hematologic, renal, hepatic and pulmonary function, as well as no history of other cancer or previous chemo/chemoradiotherapy. The study excluded patients who were unable to give informed consent, had non-resectable disease, were unable to perform CPET due to known contra-indication (e.g. lower limb dysfunction), or who declined planned surgery or neoadjuvant cancer treatments. Eligible patients were staged according to a pre-determined protocol. All patients underwent pre-treatment staging based on a pre-determined protocol. This included a medical history, physical examination, pulmonary function tests, routine hematologic and biochemical test, esophago-gastric endoscopy with histologic biopsy +/- endoscopic ultrasound, computer tomography of the neck, chest and abdomen, 18F-fluorodeoxyglucose positron-emission tomography and in special circumstances external

ultrasonography of the neck, with fine-needle aspiration of lymph nodes when cancer was suspected. Re-staging was undertaken using computer tomography of the chest and abdomen and 18F-fluorodeoxyglucose positron-emission tomography +/- laparoscopy in selected cases. Radiological responses post-chemo/chemoradiotherapy were based on definitions outlined by the RECIST version 1.1 criteria for solid target lesions¹⁶.

Study recruitment

All potentially eligible patients were identified at multi-disciplinary meetings and approached with written information. All patients provided written informed consent.

Outcome measures

Fitness. CPET was used to assess physical fitness before and following completion of chemo/chemoradiotherapy (approximately four weeks following completion of chemo/chemoradiotherapy, immediately before planned surgery) and CPET was conducted according to a published protocol^{17,18}. All CPETs were performed using identical software and hardware at each recruitment site using an electromagnetically braked cycle ergometer (Ergoline 2000), a 12-lead ECG, non-invasive blood pressure measurement and pulse oximetry, and a metabolic cart (Geratherm Respiratory GmbH, Love Medical Ltd). CPET allowed for the derivation of anaerobic threshold (AT) using the modified V-Slope method. The modified V-Slope method identifies the anaerobic threshold as the tangential breakpoint in the rate of change of VCO_2 relative to VO_2 (oxygen uptake – carbon dioxide output) from the line of unity ('line of one') during the incremental stage of the exercise test. CPET was independently reported by two independent experienced observers (SJ, DL) blinded to CPET time-point and clinical outcomes, with a third adjudicator (MAW) if >5% variance in VO_2 at AT was observed. All cancer multi-disciplinary team members including the treating surgeon, anaesthetist, oncologist and peri-operative teams were blind to all CPET data.

Health-related quality of life (HRQoL). HRQoL was measured using patient reported outcome measure (EQ-5D-5L¹⁹) questionnaire before and following completion of chemo/chemoradiotherapy (approximately four weeks following completion of chemo/chemoradiotherapy, immediately before planned surgery).

Post-operative outcome. All patients were followed-up (by staff blinded to CPET results), using the Post-Operative Morbidity Survey (POMS)²⁰ at day 3, 5, 8 and 15 post-operatively. Length of hospital stay and critical care length of stay was calculated by subtracting the discharge date from the admission date. The Revised Cardiac Risk Index (RCRI)²¹ was calculated preoperatively and the O-POSSUM score was completed postoperatively²².

Neoadjuvant chemo/chemoradiotherapy

We did not attempt to standardise chemo/chemoradiotherapy regimes. Chemotherapy regimens included: Epirubicin, Oxaliplatin, Capecitabine (EOX); Epirubicin, Cisplatin, Capecitabine (ECX)²³; Epirubicin, Cisplatin, 5-Fluorouracil (ECF)²⁴, chemotherapy as part of the ST03 trial – ECX or ECX + Bevacizumab²⁵,

chemotherapy as part of the OEO5 trial – ECX or Cisplatin and 5-Fluorouracil²⁶; chemoradiotherapy as part of the CROSS trial – Carboplatin, Paclitaxel with concurrent radiotherapy²⁷; chemoradiotherapy as part of the NEOSCOPE trial – Oxaliplatin and Capecitabine or Carboplatin and Paclitaxel with concurrent radiotherapy and induction Oxaliplatin and Capecitabine chemotherapy²⁸; Herceptin, Cisplatin and Capecitabine; Capecitabine alone; and Cisplatin alone. CROSS style radiotherapy was administered at a total radiation dose of 41.4Gy given in 23 fractions of 1.8Gy each, with 5 fractions administered per week, starting on the first date of the first chemotherapy cycle. NEOSCOPE style radiotherapy was administered at a total radiation dose of 45Gy given in 25 fractions of 1.8Gy each, with 5 fractions administered per week, starting on the first date of the first chemotherapy cycle. All patients were treated with external beam radiation. Patients were closely monitored for toxic effects of chemo/chemoradiotherapy using the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0²⁹.

Surgery

All patients underwent surgery within 4-6 weeks of chemo/chemoradiotherapy. Open, hybrid or fully minimal access approaches were used depending on patient characteristics and surgeon preference. A thorascopic assisted three-stage esophagectomy or an Ivor-Lewis esophagectomy based on tumour location was undertaken. A transthoracic approach was performed for tumours extending proximally to the tracheal bifurcation. For tumours involving the oesophagogastric junction, an Ivor-Lewis oesophagectomy resection was performed. Gastric tube reconstruction was the preferred technique for restoring intestinal continuity. Gastric surgery consisted of a radical resection of the primary tumour and at least a D1+ lymph node dissection.

Follow-up

During the first year after surgery, patients were followed up for re-admission at 30-days post-operatively, all-cause mortality at 30-days and one-year post-operatively. Additional all-cause mortality follow-up was completed at five-year post-operatively. Patients completed an EQ-5D-5L questionnaire at 30-days and one-year post-operatively.

Aims and objectives

Pre-defined primary aims briefly include:

1) observing changes in physical fitness (VO_2 at AT and VO_2 peak) following chemo/chemoradiotherapy, measured using CPET; and

2) interrogating the association of change in physical fitness following chemo/chemoradiotherapy and mortality one-year after surgery. This was evaluated in two ways: A) by evaluating the relative decrease in physical fitness associated with chemo/chemoradiotherapy and its association with mortality 1-year after surgery; and B) by evaluating whether a change in the risk stratification category (low risk VO_2 at AT >14 $\text{ml.kg}^{-1}.\text{min}^{-1}$, medium risk VO_2 at AT 11.0–14.0 $\text{ml.kg}^{-1}.\text{min}^{-1}$, high-risk VO_2 at AT 8.0–10.9 $\text{ml.kg}^{-1}.\text{min}^{-1}$, highest risk VO_2 at AT <8.0 $\text{ml.kg}^{-1}.\text{min}^{-1}$) following chemo/chemoradiotherapy would be associated with an increased one-year mortality following surgery when

compared with those that do not change their risk stratification category. Similar interrogations were undertaken for mortality at 5-years after surgery. Risk categories were defined *a priori*¹⁴.

The trial had several exploratory end points that are detailed in the study protocol¹⁴. Briefly we explored:

- 1) the relationships between baseline/relative decrease in physical fitness (VO_2 at AT and VO_2 at Peak) following chemo/chemoradiotherapy and post-operative in-hospital morbidity (measured by the Post-Operative Morbidity Survey) and patient reported quality of life (measured by EQ-5D-5L);
- 2) the ability of less fit (VO_2 at AT and VO_2 at Peak) patients to tolerate chemo/chemoradiotherapy compared to patients with a higher fitness;
- 3) the relationship between patients who tolerate chemo/chemoradiotherapy poorly and an increase in post-operative outcomes (POMS, one-year mortality, EQ-5D); and
- 4) if patients undergoing chemoradiotherapy exhibit a greater decline in physical fitness (VO_2 at AT and VO_2 at Peak) compared to patients undergoing chemotherapy.

Sample size calculation

Based on our previously published data¹⁰ demonstrating a standard deviation of the differences in VO_2 at AT values of $3.8 \text{ ml.kg}^{-1}.\text{min}^{-1}$, we calculated that 152 patients were needed to detect a difference of $1.0 \text{ ml.kg}^{-1}.\text{min}^{-1}$ of VO_2 at AT using a paired t-test at the 5% significance level with 90% power (114 patients with 80% power), assuming the standard deviation of these differences is $3.8 \text{ ml.kg}^{-1}.\text{min}^{-1}$. To detect a difference in one-year mortality rates of 23% (34% versus 11% - based on published pilot data¹⁰) between the two VO_2 at AT change groups [no change/deteriorate], we calculated that 104 patients were required using a chi-squared test at the 5% significance level with 80% power, assuming equal numbers of patients in both groups.

Statistical analysis

All data was inputted by double-data entry and validation was done according to procedures set out in the study data management and data validation plan overseen by the study management group.

Detailed statistical methods are described elsewhere¹⁴. The primary analysis was a comparison of physical fitness (VO_2 at AT) before and after chemo/chemoradiotherapy using a paired t-test. Distributional assumptions were assessed using a normal plot. Other fitness comparisons between independent patient groups were made using the two-sample t-test. The Cox proportional hazards model was used to investigate the relationship between 'change in fitness' and mortality within 5-year and the Kaplan-Meier plot was used to illustrate the survival of different patient groups. Multiple regression with backward elimination (at the 5% level) was used to investigate the relationship between post-chemo/chemoradiotherapy fitness and the various pre-chemo/chemoradiotherapy fitness variables. The predictive ability of both primary aim models to ascertain how prognostic the

relative decrease in physical fitness was evaluated. Data was adjusted for baseline fitness and "penalized" regression models which contains more factors, even when the "Rule of 10" is not met were used³⁰. Logistic regression was used to investigate the relationship between POMS morbidity and fitness. All analyses were performed with the statistical software Stata 14.0.

Results

Patient characteristics

From September 2011 to September 2016, we enrolled 160 patients (one-year mortality follow-up to September 2017). One withdrew consent and was not included in the analysis (Figure 1). Patient characteristics for the whole group are shown in Table 1. Cancer regime, tumour characteristics and radiological responses to chemo/chemoradiotherapy using RECIST v1.1 criteria are presented in Table 2. Patients who completed a pre-chemo/chemoradiotherapy CPET only (i.e. patients who did not progress to surgery due to a serious adverse event, a palliative diagnosis on restaging, death during chemo/chemoradiotherapy or progressing to surgery after a serious adverse event or no CPET; $n=23$) had lower rates of chemo/chemoradiotherapy completion (7/23 (30.4%) vs. 86/109 (78.9%)), cycles undertaken (1.9 vs. 2.9) and were found to have distant disease on restaging (6/23 (50%) vs. 6/109 (5.5%)). No adverse events during CPET were recorded.

Change in physical fitness following chemo/chemoradiotherapy

Table 3 summarises CPET data for patients who completed chemo/chemoradiotherapy. There was a significant decline in VO_2 at AT and VO_2 at Peak: $-1.25 \text{ ml.kg}^{-1}.\text{min}^{-1}$ (-1.80 to -0.69) and $-3.02 \text{ ml.kg}^{-1}.\text{min}^{-1}$ (-3.85 to -2.20); $p<0.0001$) following neoadjuvant chemo/chemoradiotherapy. Other key CPET variables are summarised in Table 3, all showing a significant reduction in fitness. Patients whose treatment pathway changed, i.e. did not complete chemo/chemoradiotherapy ($n=50$), were found to be significantly more unfit on their baseline CPET compared to patients who completed chemo/chemoradiotherapy (VO_2 at Peak 18.6 (5.7) $\text{ml.kg}^{-1}.\text{min}^{-1}$ vs. 20.8 (5.9) $\text{ml.kg}^{-1}.\text{min}^{-1}$; $p=0.025$ and work rate at peak 104.8 (47.9)W vs. 134.8 (49.6)W; $p<0.001$). Figure 2 demonstrates a graphical representation of the VO_2 at AT data pre- and post-chemo/chemoradiotherapy. Based on our predetermined risk stratification thresholds, 47% of patients changed fitness group following chemo/chemoradiotherapy (51/109), of these 10% moved to a lower risk group, i.e. improved their fitness (11/109) and 37% moved to a higher risk group (40/109), with no change in 53% (58/109).

Fitness and survival

Survival analyses was based on 100 patients (19 of whom died) who had repeat CPET following chemo/chemoradiotherapy, underwent surgery and were followed one year later. Survival analyses was also conducted on 99 patients five years later (51 of whom died). There was insufficient evidence that a change in fitness between pre- and post-chemo/chemoradiotherapy ($\text{HR}=0.88$, 95%CI: 0.75 to 1.03 , $p=0.115$) was independently associated with 1-year mortality whilst there was a significant change associated with 5-year mortality ($\text{HR} = 0.89$ (0.81 to 0.98 ; $p = 0.019$); Figure 3). There was also insufficient

Figure 1. Study enrolment and follow-up. Of the 160 patients who were enrolled, 159 had pre-neoadjuvant chemo/chemoradiotherapy (NAC/CRT) cardiopulmonary exercise testing (CPET), 27 did not undergo NAC/CRT of which 5 went straight to surgery and were excluded. 132 patients underwent NAC/CRT of which 8* went straight to surgery and a further 15 did not complete post-NAC/CRT CPET. 109 patients underwent post-NAC/CRT CPET and 108 underwent surgery. * denotes patients who went straight to surgery after either a serious adverse event during NAC/CRT or patients who did not undergo CPET after NAC/CRT.

evidence that post-chemo/chemoradiotherapy fitness was independently associated with one-year mortality (HR = 0.90, 95%CI: 0.78 to 1.03, p=0.122) and 5-year mortality (HR = 1.06

(0.98 to 1.15; p = 0.135); **Figure 4**). Pre-chemo/chemoradiotherapy (baseline) VO_2 at AT was however independently associated with 1-year mortality (HR=0.72, 95%CI: 0.59 to 0.88,

Table 1. Characteristics of all recruited patients, including patients that completed neoadjuvant chemotherapy/chemoradiotherapy and cardiopulmonary exercise testing (CPET).

Patient characteristics	All patients (n=159)	Received NAC/CRT (n=132)	Did not receive NAC/CRT (n = 27)	Had repeat CPET (n=109)	Did not have repeat CPET (n=50)
Male	114 (71.7%)	99 (75.0%)	15 (56%)	82 (75.2%)	32 (64%)
Age (years)	64.6 (9.3)	63.8 (9.2)	68.4 (8.8)	63.5 (9.0)	66.9 (9.7)
Weight (kg)	77.68 (17.2)	78.1 (15.8)	75.7 (23.1)	78.5 (15.2)	75.9 (21.0)
BMI (kg.m⁻²)	26.8 (5.2)	26.8 (4.7)	26.8 (7.1)	27.0 (4.6)	26.5 (6.3)
Smoking					
Never	42 (26.3%)	31 (23.5%)	11 (41%)	24 (22.0%)	18 (36%)
Previous	86 (54.1%)	75 (56.8%)	11 (41%)	63 (57.8%)	23 (46%)
Current	28 (17.6%)	23 (17.4%)	5 (19%)	19 (17.4%)	9 (18%)
Unknown	3 (1.9%)	3 (2.3%)	0 (0%)	3 (2.8%)	0 (0%)
Alcohol					
Never	34 (21.4%)	25 (18.9%)	9 (33%)	21 (19.3%)	13 (26%)
Minimal	51 (32.1%)	43 (32.6%)	8 (30%)	32 (29.4%)	19 (38%)
Moderate	58 (36.5%)	50 (37.9%)	8 (30%)	44 (40.4%)	14 (28%)
Heavy	12 (7.5%)	10 (7.6%)	2 (7%)	8 (7.3%)	4 (8%)
Unknown	4 (2.5%)	4 (3.0%)	0 (0%)	4 (3.7%)	0 (0%)
Hospital site					
Southampton	41 (25.8%)	41 (31.1%)	0 (0%)	35 (32.1%)	6 (12%)
Aintree	100 (62.9%)	74 (56.1%)	26 (96%)	59 (54.1%)	41 (82%)
Preston	10 (6.3%)	10 (7.6%)	0 (0%)	10 (9.2%)	0 (0%)
South Tees	8 (5.0%)	7 (5.3%)	1 (4%)	5 (4.6%)	3 (6%)
Medication					
Beta-blockers	24 (15.1%)	19 (14.4%)	5 (19%)	16 (14.7%)	8 (16%)
Diabetes medication (oral or insulin)	23 (14.5%)	18 (13.6%)	5 (19%)	15 (13.8%)	8 (16%)
Asthma (inhalers)	18 (11.3%)	15 (11.4%)	3 (11%)	12 (11.0%)	6 (12%)
Antihypertensive	55 (34.6%)	42 (31.8%)	13 (48%)	37 (33.9%)	18 (36%)
Steroids (inhaled)	5 (3.1%)	4 (3.0%)	1 (4%)	4 (3.7%)	1 (2%)
Anticoagulants (Warfarin or Novel Anticoagulants)	4 (2.5%)	4 (3.0%)	0 (0%)	3 (2.8%)	1 (2%)

Data are either n (%) or Mean (SD).

Abbreviations: CPET – cardiopulmonary exercise testing; NAC/CRT – neoadjuvant chemotherapy or chemoradiotherapy.

Note: All patients (n=159) represent those who underwent baseline assessment; received NAC/CRT (n=132) those who underwent NAC/CRT; did not receive NAC/CRT (n=27) those who did not complete NAC/CRT; had repeat CPET (n=109) those who underwent a pre- and post-NAC/CRT CPET; did not have repeat CPET (n=50) those who did not undertake a post-NAC/CRT CPET. Out of 159 patients, two patients (1%) were diagnosed with a mucinous tumour of the oesophagus (one was palliated), 31 (19%) with squamous-cell carcinoma of the oesophagus (1 oesophagogastric junction) and 126 (79%) patients were diagnosed with adenocarcinoma (oesophageal - 82 patients, gastric - 33 patients and oesophagogastric junction - 11 patients).

p=0.001) whilst there was insufficient evidence for 5-year mortality (HR = 0.97 (0.88 to 1.06; p = 0.494); [Figure 5](#)).

Considering clinical risk groups, pre-chemo/chemoradiotherapy VO₂ at AT risk group (low/medium risk vs. high/highest

Table 2. Cancer regime, tumour characteristics and radiological responses of patients who underwent neoadjuvant chemotherapy (NAC) or chemoradiotherapy (CRT).

	Patients completed NAC/CRT (n=132)	CPET Pre- and Post-NAC/CRT (n=109)	CPET Pre- NAC/CRT only (n=23)	P-value
Cancer therapy regime				
Chemotherapy (NAC)	113 (85.6%)	93 (85.3%)	20 (87.0%)	1.0
Chemoradiotherapy (CRT)	19 (14.4%)	16 (14.7%)	3 (13.0%)	
Cancer therapy regime				
Complete	93 (70.5%)	86 (78.9%)	7 (30.4%)	0.0015
Incomplete	39 (29.5%)	23 (21.1%)	16 (69.6%)	
Number of Cycles	2.8 (0.9)	2.9 (0.9)	1.9 (0.7)	0.0012
Pre-NAC/CRT Radiological Staging				
Tumour stage (T-stage)*				
T2	41 (31.1%)	32 (29.4%)	9 (39.1%)	0.826
T3	81 (61.4%)	68 (62.4%)	13 (56.5%)	
T4	10 (7.6%)	9 (8.3%)	1 (4.4%)	
Nodal stage (N-Stage)*				
N0	19 (14.4%)	14 (12.8%)	5 (21.7%)	0.276
N1	85 (64.4%)	71 (65.1%)	14 (60.9%)	
N2	26 (19.7%)	23 (21.1%)	3 (13.0%)	
N3	2 (1.5%)	1 (0.9%)	1 (4.4%)	
Post-NAC/CRT Radiological Staging^a				
Tumour stage (T-stage)*				
T0	11 (9.1%)	11 (10.1%)	0 (0%)	0.349
T1	6 (5.0%)	6 (5.5%)	0 (0%)	
T2	28 (23.1%)	26 (23.9%)	2 (16.7%)	
T3	69 (57.0%)	61 (56.0%)	8 (66.7%)	
T4	7 (5.8%)	5 (4.6%)	2 (16.7%)	
Nodal Stage (N-stage)*				
N0	51 (42.1%)	47 (43.1%)	4 (33.3%)	0.089
N1	39 (32.2%)	37 (33.9%)	2 (16.7%)	
N2	29 (24.0%)	24 (22.0%)	5 (41.7%)	
N3	2 (1.7%)	1 (0.9%)	1 (8.3%)	
Metastasis (M-stage)*				
M1	12 (9.9%)	6 (5.5%)	6 (50%)	0.0010
Tumour type				
Adenocarcinoma	106 (80.3%)	90 (82.6%)	16 (69.6%)	0.279
Squamous-cell carcinoma	25 (18.9%)	18 (16.5%)	7 (30.4%)	
Other	1 (0.8%)	1 (0.9%)	0 (0%)	

	Patients completed NAC/CRT (n=132)	CPET Pre- and Post-NAC/CRT (n=109)	CPET Pre- NAC/CRT only (n=23)	P-value
NAC/CRT radiological response^{bs}				
Stable disease	57 (44.2%)	49 (45.0%)	8 (40.0%)	0.0003
Partial response	63 (48.8%)	59 (54.1%)	4 (20.0%)	
Unknown	9 (7.0%)	1 (0.9%)	8 (40.0%)	

Data are n (%) or mean (SD) unless otherwise stated. ^a n=121, ^b n=129. ^sRadiological responses post-NAC/CRT were based on definitions outlined by the RECIST version 1.1 criteria for solid target lesions. P-value for comparison between pre- and post NAC group vs. pre-NAC group. Statistical significance was taken <0.05 and highlighted in bold.

Note: Complete cancer therapy is defined as successfully completion of all planned cycles of NAC/CRT. Incomplete cancer therapy is defined as unsuccessful completion of all planned NAC/CRT cycles for any reason. * T-stage, N-stage, M-stage both pre and post-NAC/CRT was assessed by means of computer tomography (CT) and/or endoscopic ultrasound and/or ¹⁸F-fluorodeoxyglucose positron-emission tomography, classified according to TNM v7.

Table 3. Cardiopulmonary exercise testing (CPET) variables before and after neoadjuvant chemotherapy (NAC) and chemoradiotherapy (CRT).

	Pre-NAC/CRT (n=109)	Post-CRT/NAC (n=109)	Difference (95% CI)	P-value
VO₂ at AT (ml.min⁻¹)	0.91 (0.27)	0.8 (0.26)	-0.11 (-0.16 to -0.07)	<0.0001
VO₂ at AT (ml.kg⁻¹.min⁻¹)	11.72 (2.97)	10.47 (3.18)	-1.25 (-1.80 to -0.69)	<0.0001
VO₂ at Peak (ml.min⁻¹)	1.62 (0.51)	1.37 (0.49)	-0.25 (-0.32 to -0.18)	<0.0001
VO₂ at Peak (ml.kg⁻¹.min⁻¹)	20.81 (5.93)	17.79 (5.58)	-3.02 (-3.85 to -2.20)	<0.0001
WR at AT (W)	62.9 (30.76)	53.19 (28.35)	-9.71 (-14.37 to -5.04)	0.0001
WR at Peak (W)	134.8 (49.6)	117.39 (48.29)	-17.39 (-24.08 to -10.69)	<0.0001
V_E/VCO₂ at AT	35.11 (4.50)	36.96 (5.93)	1.85 (0.94 to 2.76)	<0.0001
V_E/VCO₂ at Peak	35.89 (4.43)	37.61 (5.73)	1.73 (0.96 to 2.49)	<0.0001
V_E/VO₂ at AT	29.49 (4.44)	32.65 (6.46)	3.15 (2.10 to 4.21)	<0.0001
V_E/VO₂ at Peak	41.86 (7.40)	45.73 (10.14)	3.87 (2.50 to 5.25)	<0.0001
PETCO₂ at AT	37.52 (3.20)	35.95 (5.07)	-1.57 (-2.48 to -0.66)	0.0009
PETCO₂ at Peak	35.39 (3.64)	34.18 (4.17)	-1.20 (-1.77 to -0.63)	0.0001
VO₂/HR at AT (ml.beat⁻¹)	8.84 (2.68)	7.70 (2.31)	-1.13 (-1.48 to -0.79)	<0.0001
VO₂/HR at Peak (ml.beat⁻¹)	11.47 (3.27)	9.98 (3.12)	-1.49 (-1.87 to -1.11)	<0.0001

Data are mean (SD) unless otherwise stated. Statistical significance was taken as <0.05 and highlighted in bold.

Abbreviations: NAC (neoadjuvant chemotherapy), CRT (neoadjuvant chemoradiotherapy), VO₂ at AT (oxygen uptake at anaerobic threshold), VO₂ at Peak (oxygen uptake at peak exercise), WR at AT (work rate at anaerobic threshold), WR at Peak (work rate at peak exercise), V_E/VCO₂ at AT (ventilatory equivalent for carbon dioxide at the anaerobic threshold), V_E/VCO₂ at Peak (ventilatory equivalent for carbon dioxide at peak exercise), V_E/VO₂ at AT (ventilatory equivalent for oxygen at the anaerobic threshold), V_E/VO₂ at Peak (ventilatory equivalent for oxygen at peak exercise), PETCO₂ at AT (end tidal carbon dioxide at the anaerobic threshold), PETCO₂ at Peak (end tidal carbon dioxide at peak exercise), VO₂/HR at AT (oxygen pulse at the anaerobic threshold), VO₂/HR at Peak (oxygen pulse at peak exercise)

risk) was associated with mortality at one-year (HR=7.06; 95%CI: 2.04 to 24.40; p=0.002) whilst there was insufficient evidence for mortality at five-year follow (HR = 1.39 (0.80 to 2.41; p=0.237)) (Figure 6). Post-chemo/chemoradiotherapy showed weaker evidence for an association at one year (HR=3.29;

95%CI: 0.95 to 11.36; p=0.06) and there was insufficient evidence for five-year mortality (HR = 0.79 (0.46 to 1.39; p = 0.426) (Figure 7). A weak relationship between change in fitness risk group and survival at one year was noted (Better HR=0.78, 95%CI: 0.17 to 3.48; Worse HR=0.53, 95%CI: 0.17 to 1.64;

Figure 2. A ladder plot of oxygen uptake at anaerobic threshold (VO_2 at AT in $\text{ml.kg}^{-1}.\text{min}^{-1}$) pre (1) and post (2) chemo/chemoradiotherapy (NAC/CRT).

Figure 3. Kaplan-Meier plot of the estimated overall 5-year survival among patients with oesophago-gastric cancer who underwent CPET pre-and post-NAC/CRT followed by surgery, based on their change in VO_2 at AT risk stratification category following chemo/chemoradiotherapy (NAC/CRT).

Figure 4. Kaplan-Meier plot of the estimated overall 5-year survival among patients with oesophago-gastric cancer who underwent CPET pre-and post-NAC/CRT followed by surgery, based on their **post-chemo/chemoradiotherapy (NAC/CRT) VO_2 at AT risk stratification category**. Predefined risk stratification categories were defined as low risk VO_2 at AT $>14\text{ml.kg}^{-1}\text{min}^{-1}$, medium risk VO_2 at AT $11.0\text{--}14.0\text{ml.kg}^{-1}\text{min}^{-1}$, high-risk VO_2 at AT $8.0\text{--}10.9\text{ml.kg}^{-1}\text{min}^{-1}$, highest risk VO_2 at AT $<8.0\text{ml.kg}^{-1}\text{min}^{-1}$.

Figure 5. Kaplan-Meier plot of the estimated overall 5-year survival among patients with oesophago-gastric cancer who underwent CPET pre-and post-NAC/CRT followed by surgery, based on their **pre-chemo/chemoradiotherapy (NAC/CRT) VO_2 at AT risk stratification category**. Predefined risk stratification categories were defined as low risk VO_2 at AT $>14\text{ml.kg}^{-1}\text{min}^{-1}$, medium risk VO_2 at AT $11.0\text{--}14.0\text{ml.kg}^{-1}\text{min}^{-1}$, high-risk VO_2 at AT $8.0\text{--}10.9\text{ml.kg}^{-1}\text{min}^{-1}$, highest risk VO_2 at AT $<8.0\text{ml.kg}^{-1}\text{min}^{-1}$.

Figure 6. A Kaplan-Meier plot of the estimated overall 5-year survival estimates among patients with oesophageal, esophagogastric-junction and gastric cancer who underwent CPET pre-and post-chemotherapy or chemoradiotherapy (NAC/CRT) followed by surgery. Patients are split based on their pre-NAC/CRT VO₂ at AT using predefined risk stratification categories (low risk VO₂ at AT >14ml.kg⁻¹.min⁻¹, medium risk VO₂ at AT 11.0-14.0ml.kg⁻¹.min⁻¹, high-risk VO₂ at AT 8.0-10.9ml.kg⁻¹.min⁻¹, highest risk VO₂ at AT <8.0ml.kg⁻¹.min⁻¹).

Figure 7. Kaplan-Meier plot of the estimated overall 5-year survival estimates among patients with oesophageal, esophagogastric-junction and gastric cancer who underwent CPET pre-and post-chemotherapy or chemoradiotherapy (NAC/CRT) followed by surgery. Patients are split based on their post-NAC/CRT VO₂ at AT using predefined risk stratification categories (low risk VO₂ at AT >14ml.kg⁻¹.min⁻¹, medium risk VO₂ at AT 11.0-14.0ml.kg⁻¹.min⁻¹, high-risk VO₂ at AT 8.0-10.9ml.kg⁻¹.min⁻¹, highest risk VO₂ at AT <8.0ml.kg⁻¹.min⁻¹).

p=0.550) whilst a stronger relationship was noted at 5 years (Better HR = 1.09, 95%CI: 0.48 to 2.48; Worse HR = 0.52, 95%CI: 0.27 to 1.01; p=0.097).

Pre-chemo/chemoradiotherapy VO₂ at Peak was also independently associated with 1-year mortality (HR=0.85, 95%CI: 0.76 to 0.95, p=0.005). There was no evidence of an association between VO₂ at Peak post-chemo/chemoradiotherapy or relative change in VO₂ at Peak from pre- to post-chemo/chemoradiotherapy. Following adjustment for post-chemo/

chemoradiotherapy VO₂ at Peak, the relative change in VO₂ at Peak following chemo/chemoradiotherapy was associated with 1-year mortality (HR=0.85, 95%CI: 0.74 to 0.98, p=0.023).

Fitness and post-operative outcomes

Of the 109 patients who complete chemo/chemoradiotherapy, 108 underwent surgery (100 patients had complete pre- and post-chemo/chemoradiotherapy CPET data as well as surgical outcomes). Surgery and histopathological outcomes are summarised in Table 4. A total 6% of patients underwent a palliative

Table 4. Surgery and Histopathological Outcomes.

	Pre-and post-NAC/CRT data and surgery (n=100)	Pre-NAC/CRT data and surgery (n=8)	P-value
Operation			
Esophagectomy	71 (71%)	4 (50.0%)	0.324
Gastrectomy	23 (23%)	3 (37.5%)	
Palliative	6 (6%)	1 (12.5%)	
Operation type			
Unknown	0 (0%)	0 (0%)	0.605
Open	35 (35%)	3 (37.5%)	
Laparoscopic	58 (58%)	4 (50%)	
Laparoscopic converted to open	1 (1%)	0 (0%)	
Palliative resection	6 (6%)	1 (12.5%)	
Pathology staging			
Tumour stage (T-stage)^{a*}			
0	16 (15.0%)	0 (0%)	0.459
1a +1b	11 (11.7%)	1 (14.3%)	
2 +2a	14 (14.9%)	2 (28.6%)	
3	47 (50.0%)	3 (42.9%)	
4	6 (6.4%)	1 (14.3%)	
Nodal stage (N-Stage)^{a*}			
0	43 (45.7%)	4 (57.1%)	1
1	25 (26.6%)	2 (28.6%)	
2	18 (19.2%)	1 (14.3%)	
3	5 (5.3%)	0 (0%)	
3a	3 (3.2%)	0 (0%)	
Resection (R0/R1)^a			
0	75 (79.8%)	6 (85.7%)	1
1	19 (20.2%)	1 (14.3%)	
Tumour Regression Grade^b			
1	15 (16.0%)	0 (0%)	0.579
2	10 (10.6%)	1 (16.7%)	

	Pre-and post-NAC/CRT data and surgery (n=100)	Pre-NAC/CRT data and surgery (n=8)	P-value
3	16 (17.0%)	2 (33.3%)	
4	23 (24.5%)	2 (33.3%)	
5	30 (31.9%)	1 (16.7%)	
EMVI (yes)^a	28 (29.8%)	1 (14.3%)	0.670
Differentiation^c			
Moderate	35 (36.8%)	2 (28.6%)	0.695
None	13 (13.7%)	0 (0%)	
Poor	42 (44.2%)	5 (71.4%)	
Well	5 (5.3%)	0 (0%)	

Data are n (%) unless otherwise stated. Statistical significance was taken as <0.05 and highlighted in bold.

Abbreviations: NAC (neoadjuvant chemotherapy), CRT (neoadjuvant chemoradiotherapy). * T-stage and N-stage classified according to TNM v7. ^a n=101, ^b n=100, ^c n=102. ^d Tumor Regression Grade (TRG) was based on definitions outlined by the Mandard score. EMVI – Extra mural venous invasion. RO – complete resection with no tumor within 1mm of the resection margin.

bypass, 57% of patients underwent a laparoscopic operation with only one patient having a conversion to open surgery. An R0 resection was achieved in 75% of patients. A complete pathological response (TRG1) was achieved in 14%. Table 5 summarizes the post-operative outcomes as defined by POMS at Day3, 5, 8 and 15. Of note, on Day 8, 24% of patients had a complication in the low-risk group, whilst 46% of patients still had a complication in the highest risk. Median length of stay was 12 days for the low-risk group and 13.5 days in the highest risk group. Seven patients in the low/medium risk groups died post-operatively at 1-year (11.6%) whilst 18 patients died in the high/highest risk groups (36.7%). Thirty-one patients in the low/medium risk groups died post-operatively at five-years (51.6 %) whilst 28 patients died in the high/highest risk groups (57.1 %). There was insufficient evidence of an association found between POMS at Day 3, 5, 8 and 15 and pre- chemo/chemoradiotherapy VO₂ at AT (OR=1.04 95%CI: 0.85 to 1.27; p=0.730). Further, insufficient evidence of relationships was found with either post-chemo/chemoradiotherapy fitness or change in fitness. Similar results were seen for VO₂ at Peak. Of note 46% of highest risk patients were discharged back to their own home post-operatively (compared with 95% in the low-risk group), and 46% of patients in the high-risk group were re-admitted within 30-days (compared with 5% in the low-risk group).

Fitness and quality of life

We found no evidence of an association between changes in EQ-5D-5L and the relative change in VO₂ at AT or VO₂ peak following chemo/chemoradiotherapy at 30-days and one-year post-operatively (Spearman correlation 30-days r=0.062, p=0.611 and r=0.10, p=0.393; 1-year r=0.162, p=0.191 and r=0.141, p=0.253 respectively).

Chemo/chemoradiotherapy adverse effects and tolerability

A patient's ability to complete the planned full cycles of chemo/chemoradiotherapy (tolerability) as a function of their baseline fitness was assessed. Adverse events encountered during chemotherapy and chemoradiotherapy are presented in Table 6.

No association between VO₂ at AT or VO₂ peak and tolerability was found (p=0.161 and p=0.057). One-year survival was no better for patients who tolerated chemo/chemoradiotherapy (HR = 0.42, 95%CI: 0.17 to 1.06; p=0.067). Additionally, there was no evidence that either morbidity at day 5 or EQ-5D at 30-days post-operatively was associated with tolerance (p=0.149 and p=0.132).

Change in fitness with chemotherapy vs. chemoradiotherapy

A substantial clinically important significant difference in VO₂ at AT was observed between patients undergoing chemoradiotherapy vs. chemotherapy groups (-2.7(3.7) ml.kg⁻¹.min⁻¹ vs. -0.9(2.8) ml.kg⁻¹.min⁻¹; p=0.025). However, a non-significant difference in VO₂ at Peak, was observed between both groups (-3.8(5.7) ml.kg⁻¹.min⁻¹ vs. -2.8(4.2) ml.kg⁻¹.min⁻¹; p=0.380).

Discussion

This prospective, observer blinded, multi-centre, observational, cohort study in patients undergoing multimodal neoadjuvant cancer therapies for locally advanced OG cancers showed a significant decline in objectively measured fitness (VO₂ at AT and VO₂ peak) following chemo/chemoradiotherapy. Importantly, baseline fitness (VO₂ at AT and VO₂ peak) was strongly associated with mortality at one-year. Finally, we

Table 5. Post-operative outcomes for low, medium, high and highest risk groups categorised by pre-chemotherapy/chemoradiotherapy oxygen uptake at anaerobic threshold (ml.kg⁻¹.min⁻¹).

	Low (n=21)	Medium (n=39)	High (n=38)	Highest (n=11)
Post-Operative Morbidity Survey (POMS)				
Day 3 ^a	20 (95.2%)	31 (79.5%)	33 (86.8%)	10 (90.9%)
Day 5 ^b	20 (95.2%)	30 (76.9%)	26 (68.4%)	7 (63.6%)
Day 8 ^c	5 (23.8%)	21 (53.8%)	20 (52.6%)	5 (45.5%)
Day 15 ^d	4 (19.0%)	7 (17.9%)	5 (13.2%)	1 (9.1%)
Length of Stay (days)^a	12 (9-15)	13 (10-18)	11 (9-14.5)	13.5 (7-16)
O-POSSUM Physiology score^a	16.4 (3.3)	17.0 (3.4)	17.7 (2.9)	17.4 (2.8)
O-POSSUM Mortality score^a	7.8 (4.9)	10.0 (6.0)	12.6 (6.7)	11.5 (5.0)
RCRI (total score)^a	1.0 (0.2)	1.1 (0.4)	1.2 (0.5)	1.5 (0.8)
Level 2/3 Length of Stay^a	4 (3-7)	4 (3-5)	4 (2-6)	4 (3-5)
Discharge Destination				
Home	20 (95.2%)	39 (100%)	30 (78.9%)	5 (45.5%)
Intermediate care	0 (0%)	0 (0%)	5 (13.1%)	3 (9.1%)
Nursing home	0 (0%)	0 (0%)	3 (7.9%)	3 (9.1%)
Rehabilitation hospital	1 (4.8%)	0 (0%)	0 (0%)	0 (0%)
30-day readmission^d	1 (4.8%)	5 (12.8%)	6 (15.7%)	5 (45.5%)
1-year Mortality	2 (9.5%)	5 (12.8%)	14 (36.8%)	4 (36.4%)
5-year Mortality	9 (42.9%)	24 (61.5%)	23 (60.5%)	5 (45.4%)

Data are either n (%), mean (SD) or median (IQR) unless otherwise stated.

Abbreviations: O-POSSUM – Oesophago-gastric specific Physiological and Operative Severity Score for the enumeration of Mortality and morbidity. ^a n=100, ^b n=80, ^c n=26, ^d n=102

Note: VO₂ at AT (ml.kg⁻¹.min⁻¹) predefined risk stratification categories (low risk VO₂ at AT >14ml.kg⁻¹.min⁻¹, medium risk VO₂ at AT 11.0-14.0ml.kg⁻¹.min⁻¹, high-risk VO₂ at AT 8.0-10.9ml.kg⁻¹.min⁻¹, highest risk VO₂ at AT <8.0ml.kg⁻¹.min⁻¹).

observed a higher incidence of post-operative morbidity and a longer length of hospital stay in the high/highest risk groups, as well as a greater decline in VO₂ at AT following chemoradiotherapy compared to chemotherapy treatment.

Multimodal neoadjuvant therapies for OG cancer patients are associated with marginal gains in overall survival^{6,31}. However, these treatments might be accompanied with a significant cost to patient's fitness. Although overall survival has improved for oesophageal patients, a network meta-analysis showed that chemoradiotherapy increased the risk of post-operative mortality when compared to chemotherapy or surgery alone, but improved tumour regression was found³². Similarly, overall survival was moderately improved in gastric cancer patients undergoing platinum based triplet regimens^{6,33}, however such patients experience significant peri-chemotherapy morbidity with increased lymphocytopenia and hemoglobinopathy. In

some patients, pre-operative treatment might have no meaningful benefit and may even cause harm³⁴.

The reliability and association of selected CPET variables with post-operative outcome has been established for major abdominal surgery⁹, however this relationship has not been adequately investigated in OG patients, where surgery is frequently in two body cavities. At present, there is little evidence supporting the use of pre-operative CPET to aid shared decision making and guide perioperative care prior to OG cancer surgery. Conclusive evidence regarding objective changes in fitness after neoadjuvant treatment for OG cancer and any possible relationship with operative outcomes does not exist. So far small, unblinded, single-centre, observational studies report similar significant declines in fitness with chemo/chemoradiotherapy, associations between low fitness and higher post-operative cardio-respiratory complications and

Table 6. Adverse events during chemotherapy and chemoradiotherapy – events of grade ≥ 2 during chemotherapy or chemoradiotherapy.

Regime	Adverse Events: Number of events/ total number of patients	Adverse Event Description
Epirubicin, Oxaliplatin, Capecitabine (EOX)	0/15	
Epirubicin, Cisplatin, Capecitabine (ECX)	18/71	Neutropenia– 3 Acute kidney injury – 9 Proximal lower limb deep vein thrombosis – 2 Pulmonary embolism – 1 Cerebrovascular accident - 2 Dysphagia and stent placement – 1 Death – 2
Epirubicin, Cisplatin, 5-Fluorouracil (ECF)	1/3	Neutropenia– 1
STO3 trial – ECX alone	1/4	Pulmonary embolism – 1
STO3 trial –ECX + Bevacizumab	1/4	Oesophageal perforation - 1
OEO5 trial – ECX alone	1/2	Death - 1
OEO5 trial – Cisplatin and 5-Fluorouracil	0/6	
CROSS trial – Carboplatin, Paclitaxel with concurrent radiotherapy	0/10	
NEOSCOPE trial – Oxaliplatin and Capecitabine with concurrent radiotherapy	1/6	Death - 1
NEOSCOPE trial –Carboplatin and Paclitaxel with concurrent radiotherapy	0/3	
Herceptin, Cisplatin and Capecitabine	0/2	
Capecitabine alone	0/1	
Cisplatin alone	4/5	Death – 1 Neutropenia – 1 Acute kidney injury– 1 Acute psychosis - 1

Adverse events were graded according to the National Cancer Institute's Common Terminology Criteria for Adverse Events, version 3.0. Neutropenia is defined as absolute neutrophil count $<1.0 \times 10^9/L$; Creatinine >1.5 upper limit for normal

Of 132 patients receiving NAC/CRT; 86% underwent chemotherapy alone (38 patients (34%) incomplete treatment) and 14% underwent chemoradiotherapy (1 patient (5%) incomplete treatment). Acute kidney injury with a rise in serum creatinine more than 1.5 times the upper limit of normal was the most common adverse event encountered. Five deaths were recorded during NAC/CRT.

sustained reductions in fitness between the end of neoadjuvant chemotherapy (NAC) and surgery^{10–13}.

This study reports clinically important reductions in fitness associated with chemo/chemoradiotherapy, validating our initial pilot and single-centre observations^{10–13}. This may be attributed to changes in metabolic health such as changes in body composition (sarco-cachexia) due to neoadjuvant treatments, recently recognised in OG cancer cohorts^{35–37}. Sarcopenia and sarcopenic obesity are associated with early termination of neoadjuvant treatments, dose limiting toxicity, operative morbidity, poor oncological outcomes, including poor survival³⁸. Sarcopenia, like poor fitness is a modifiable risk factor. Multimodal

prehabilitation interventions might rescue the decline in fitness and body composition seen with neoadjuvant treatments^{39–41}, however, improving baseline fitness (associated with one-year mortality) is challenging and a broader public health issue. Whilst mechanisms of reduced fitness are unclear, a reduction in muscle mass is also known to reduce ventilatory efficiency. This study demonstrates a reduction in ventilatory equivalent for carbon dioxide (V_E/VCO_2) at AT and peak. Moreover, mitochondrial dysfunction and sarcopenia are attributed to toxicity from neoadjuvant platinum-based compounds. Mitochondrial DNA, cell cycle arrest⁴², sustained activation of degradative proteasome and autophagy systems⁴³, and altered NF- κ B signalling⁴⁴ are linked to platinum based chemotherapy

toxicity. Ultimately, these changes induce mitochondrial and cellular protein damage, leading to autologous destruction – myophagy and muscle wasting⁴⁵ seen in the present study as a reduction in oxygen utilisation and power output at AT and peak exercise.

Objective fitness assessment prior to chemo/chemoradiotherapy provides useful information to guide personalized shared decision-making around operative risk and survival for the multi-disciplinary team and the patient. It may also guide neoadjuvant chemo/chemoradiotherapy choices, by directing more aggressive chemo/chemoradiotherapy choices to fitter individuals or even guide delays in the cancer treatment pathway to institute an intervention before neoadjuvant treatment in selected individuals. Informing the selection of risk-reducing neoadjuvant treatment options when baseline fitness is already compromised (e.g. selection of NAC over chemoradiotherapy for low baseline fitness patients), or even guide shared-decision making around palliative options might be clinically desirable. On the contrary, giving higher doses of chemotherapy or chemoradiation, or even more aggressive FLOT-based chemotherapy³² in patients who are objectively in low-risk fitness categories might improve outcomes for selected patients. Objective risk-stratification might also direct higher levels of peri/post-operative care in unfit individuals, thereby improve utilisation of scarce critical care resources. The more information we are able to obtain on the patient's physiology, metabolic health and tumour status, the more we are able to effectively inform patients and their relatives in their decision-making process and consent. These data might also suggest the potential utility of tailored prehabilitation interventions during neoadjuvant treatments to optimise metabolic health and respiratory function, however this needs further evaluation as maintaining/improving fitness during the whole cancer pathway might impart some long-term benefits^{40,46,47}.

There are several strengths to this study. Firstly, it validates the findings of other smaller cohort studies utilising rigorous, prospective, observer-blinded methodology and providing multi-centre generalisability. It describes a novel, strongly independent association between baseline physical fitness (pre- chemo/chemoradiotherapy) and one-year overall survival, but unfortunately not between post-treatment fitness and survival. These observations emphasise the need for physiological staging, including evaluation of physical fitness, to be undertaken prior to chemo/chemoradiotherapy, and that fitness assessment after chemo/chemoradiotherapy might not play a role in predicting long-term outcomes. Further work is needed to establish this. Methodological rigor around dual-expert, blind CPET reporting and a low risk of confounding by indication is also a strength.

Limitations of this study included, a lack of accurate operative definitions, the heterogeneity of the cancer type and cancer treatments. This, however, is a pragmatic study and restrictions based around operative technique and care treatment were felt to be overly restrictive and not generalisable. Further, inability to successfully interrogate the association between fitness, morbidity and patient reported quality of life was due

to a lack of statistical power. Furthermore, neither changes in physical fitness nor fitness-risk group following chemo/chemoradiotherapy were independently associated with one-year survival due to a lack of statistical power.

In conclusion, neoadjuvant treatment prior to OG cancer surgery significantly reduces physical fitness, with patients who are unfit at baseline having lower survival at one-year post-operatively.

Data availability

Underlying data

Harvard Dataverse: Replication Data for Demographics: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/ILSTAD>⁴⁸.

Harvard Dataverse: Replication Data for EQ-5D-5L Pre NAC: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/Z0H41K>⁴⁹.

Harvard Dataverse: Replication Data for EQ-5D-5L Post NAC: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/RNVIHN>⁵⁰.

Harvard Dataverse: Replication Data for RCRI: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/GQT-BTM>⁵¹.

Harvard Dataverse: Replication Data for O-POSSUM: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/XSJHSZ>⁵².

Harvard Dataverse: Replication Data for POMS Day 3: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/GTE1QJ>⁵³.

Harvard Dataverse: Replication Data for POMS Day 5: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/XIXD2L>⁵⁴.

Harvard Dataverse: Replication Data for POMS Day 15: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/BAHW00>⁵⁵.

Harvard Dataverse: Replication Data for Op Details: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/LOB8PG>⁵⁶.

Harvard Dataverse: Replication Data for Histology: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/DSC-SOI>⁵⁷.

Harvard Dataverse: Replication Data for EQ-5D-5L 30 days post surgery: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/ZDR7C1>⁵⁸.

Harvard Dataverse: Replication Data for EQ-5D-5L 1 year post surgery: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/AGC3IL>⁵⁹.

Harvard Dataverse: Replication Data for CPET Variables: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/IM11CG>⁶⁰.

Reporting guidelines

Harvard Dataverse: STROBE checklist for 'The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'. <https://doi.org/10.7910/DVN/NUV1OI>⁶¹.

Data are available under the terms of the [Creative Commons Zero](#) "No rights reserved" data waiver (CC0 1.0 Public domain dedication).

Acknowledgements

The authors would like to thank the National Institute for Health Research (NIHR) who funded this work under the Research Patient Benefit Programme (PB-PG-0609-18262). Funders and study sponsors had no role in the study design, in the collection, analysis and interpretation of data; in the writing of the manuscript; and in the decision to submit the manuscript for publication. No commercial support was involved in the study. No one who is not an author contributed to the manuscript. All authors vouch for the accuracy and completeness of the reported data and the fidelity of the study to the protocol. This work was undertaken whilst MW and MPWG were funded by

the National Institute of Health Research and the Royal College of Anaesthetists British Oxygen Company Fellowship awarded by the National Institute of Academic Anaesthesia for the Fit-4-Surgery programme of research. MPWG is an NIHR Senior Investigator.

These data were presented as an oral presentation as part of the EBPOM UK, London, July 2018

Fit-4-Surgery Consortium Collaborators: Andrew Bateman^{1,2}, Timothy J Underwood^{1,9}, James Byrne^{1,9}, James Ryan⁷, Richard Sturgess¹⁰, Miland Shrotri¹¹, Mohammed Javed¹¹, Andrew Masters¹¹, Iftikhar Khan¹¹, Adrian Kendrick¹²

¹Academic Unit of Cancer Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. SO16 6YD.

²Integrative Physiology and Critical Illness Group, Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, UK. SO16 6YD.

³Acute Perioperative and Critical Care Research Group, Southampton NIHR Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK. SO16 6YD.

⁴Department of Statistical Science, University College London, London, UK. W1T 7PJ.

⁵Centre for Anaesthesia, Institute of Sport Exercise and Health, University College London Hospitals NIHR Biomedical Research Centre, London, UK. W1T 7HA.

⁶Department of Critical Care and Anaesthesia, Lancashire Teaching Hospitals NHS Foundation Trust, Lancashire, UK. PR7 1PP.

⁷Department of Critical Care and Anaesthesia, The James Cook University Hospital, Middlesbrough, UK. TS4 3BW.

⁸Department of Respiratory Research, University of Liverpool, University Hospitals Aintree, Liverpool, UK. L9 7AL.

⁹Department of Upper Gastro-intestinal Surgery, University Hospital Southampton NHS Foundation Trust, Southampton, UK. SO16 6YD.

¹⁰Department of Gastroenterology, University Hospital Aintree, Liverpool, UK. L9 7AL.

¹¹Department of Surgery, University Hospital Aintree, Liverpool, UK. L9 7AL.

¹²Department of Physiological Sciences, University of Bristol, Bristol, UK. BS8 1TH.

References

1. van Hagen P, Hulshof MCC, van Lanschot JJB, *et al.*: **Preoperative chemoradiotherapy for esophageal cancer.** *N Engl J Med.* 2012; **367**(9): 872–4. [PubMed Abstract](#) | [Publisher Full Text](#)
2. Shapiro J, van Lanschot JJB, Hulshof MCC, *et al.*: **Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial.** *Lancet Oncol.* 2015; **16**(9): 1090–1098. [PubMed Abstract](#) | [Publisher Full Text](#)
3. Cunningham D, Stenning SP, Smyth EC, *et al.*: **Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.** *Lancet Oncol.* 2017; **18**(3): 357–70. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Cunningham D, Allum W, Stenning SP, *et al.*: **Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.** *N Engl J Med.* 2006; **355**(1): 11–20. [PubMed Abstract](#) | [Publisher Full Text](#)
5. Kidane B, Coughlin S, Vogt K, *et al.*: **Preoperative chemotherapy for resectable thoracic esophageal cancer.** *Cochrane Database Syst Rev.* 2015; **2015**(5): CD001556. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
6. Miao ZF, Liu XY, Wang ZN, *et al.*: **Effect of neoadjuvant chemotherapy in patients with gastric cancer: a PRISMA-compliant systematic review and meta-analysis.** *BMC Cancer.* 2018; **18**(1): 118. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
7. Wijesundera DN, Pearse RM, Shulman MA, *et al.*: **Assessment of functional capacity before major non-cardiac surgery: an international, prospective cohort study.** *Lancet.* 2018; **391**(10140): 2631–40. [PubMed Abstract](#) | [Publisher Full Text](#)
8. Levett DZH, Edwards M, Grocott M, *et al.*: **Preparing the patient for surgery to improve outcomes.** *Best Pract Res Clin Anaesthesiol.* 2016; **30**(2): 145–57. [PubMed Abstract](#) | [Publisher Full Text](#)
9. Moran J, Wilson F, Guinan E, *et al.*: **Role of cardiopulmonary exercise testing as a risk-assessment method in patients undergoing intra-abdominal surgery: A systematic review.** *Br J Anaesth.* 2016; **116**(2): 177–91. [PubMed Abstract](#) | [Publisher Full Text](#)
10. Jack S, West MA, Raw D, *et al.*: **The effect of neoadjuvant chemotherapy on physical fitness and survival in patients undergoing oesophagogastric cancer surgery.** *Eur J Surg Oncol.* 2014; **40**(10): 1313–20. [PubMed Abstract](#) | [Publisher Full Text](#)
11. Thomson IG, Wallen MP, Hall A, *et al.*: **Neoadjuvant therapy reduces cardiopulmonary function in patients undergoing oesophagectomy.** *Int J Surg.* 2018; **53**: 86–92. [PubMed Abstract](#) | [Publisher Full Text](#)
12. Moyes LH, McCaffery CJ, Carter RC, *et al.*: **Cardiopulmonary exercise testing as a predictor of complications in oesophagogastric cancer surgery.** *Ann R Coll Surg Engl.* 2013; **95**(2): 125–30. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
13. Navidi M, Phillips AW, Griffin SM, *et al.*: **Cardiopulmonary fitness before and after neoadjuvant chemotherapy in patients with oesophagogastric cancer.** *Br J Surg.* 2018; **105**(7): 900–906. [PubMed Abstract](#) | [Publisher Full Text](#)
14. West MA, Loughney L, Ambler G, *et al.*: **The effect of neoadjuvant chemotherapy and chemoradiotherapy on exercise capacity and outcome following upper gastrointestinal cancer surgery: an observational cohort study.** *BMC Cancer.* 2016; **16**(1): 710. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
15. **Repository: STROBE checklist for 'The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study'.** 2021. [Publisher Full Text](#)
16. Eisenhauer EA, Therasse P, Bogaerts J, *et al.*: **New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1).** *Eur J Cancer.* 2009; **45**(2): 228–47. [PubMed Abstract](#) | [Publisher Full Text](#)
17. Levett DZH, Jack S, Swart M, *et al.*: **Preoperative Cardiopulmonary Exercise Testing (PCPET): consensus clinical guidelines on indications, organisation, conduct and physiological interpretation.** *Br J Anaesth.* 2018; **120**(3): 484–500. [PubMed Abstract](#) | [Publisher Full Text](#)
18. West MA, Lythgoe D, Barben CP, *et al.*: **Cardiopulmonary exercise variables are associated with postoperative morbidity after major colonic surgery: A prospective blinded observational study.** *Br J Anaesth.* 2014; **112**(4): 665–71. [PubMed Abstract](#) | [Publisher Full Text](#)
19. Janssen MF, Pickard AS, Golicki D, *et al.*: **Measurement properties of the EQ-5D-5L compared to the EQ-5D-3L across eight patient groups: A multi-country study.** *Qual Life Res.* 2013; **22**(7): 1717–27. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
20. Grocott MPW, Browne JP, Van der Meulen J, *et al.*: **The Postoperative Morbidity Survey was validated and used to describe morbidity after major surgery.** *J Clin Epidemiol.* 2007; **60**(9): 919–28. [PubMed Abstract](#) | [Publisher Full Text](#)
21. Lee TH, Marcantonio ER, Mangione CM, *et al.*: **Derivation and Prospective Validation of a Simple Index for Prediction of Cardiac Risk of Major Noncardiac Surgery.** *Circulation.* 1999; **100**(10): 1043–9. [PubMed Abstract](#) | [Publisher Full Text](#)
22. Tekkis PP, McCulloch P, Poloniecki JD, *et al.*: **Risk-adjusted prediction of operative mortality in oesophagogastric surgery with O-POSSUM.** *Br J Surg.* 2004; **91**(3): 288–95. [PubMed Abstract](#) | [Publisher Full Text](#)
23. Cunningham D, Starling N, Rao S, *et al.*: **Capecitabine and Oxaliplatin for Advanced Esophagogastric Cancer.** *N Engl J Med.* 2008; **358**(1): 36–46. [PubMed Abstract](#) | [Publisher Full Text](#)
24. Cunningham D, Allum WH, Stenning SP, *et al.*: **Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer.** *N Engl J Med.* 2006; **355**(1): 11–20. [PubMed Abstract](#) | [Publisher Full Text](#)
25. Cunningham D, Stenning SP, Smyth EC, *et al.*: **Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): primary analysis results of a multicentre, open-label, randomised phase 2-3 trial.** *Lancet Oncol.* 2017; **18**(3): 357–370. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
26. Alderson D, Langley RE, Nankivell MG, *et al.*: **Neoadjuvant chemotherapy for resectable oesophageal and junctional adenocarcinoma: results from the UK Medical Research Council randomised OEO5 trial (ISRCTN 01852072).** *J Clin Oncol.* 2015; **33**: 4002. [Publisher Full Text](#)
27. van Hagen P, Hulshof MCCM, van Lanschot JJB: **Preoperative chemoradiotherapy for esophageal or junctional cancer.** *N Engl J Med.* 2012; **366**(22): 2074–84. [PubMed Abstract](#) | [Publisher Full Text](#)
28. Mukherjee S, Hurt CN, Gwynne S, *et al.*: **NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.** *BMC Cancer.* 2015; **15**: 48. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
29. Trotti A, Colevas AD, Setser A, *et al.*: **CTCAE v3.0: Development of a comprehensive grading system for the adverse effects of cancer treatment.** *Semin Radiat Oncol.* 2003; **13**(3): 176–81. [PubMed Abstract](#) | [Publisher Full Text](#)
30. Ambler G, Seaman S, Omar RZ: **An evaluation of penalised survival methods for developing prognostic models with rare events.** *Stat Med.* 2012; **31**(11–12): 1150–61. [PubMed Abstract](#) | [Publisher Full Text](#)
31. Chan KKW, Saluja R, Delos Santos K, *et al.*: **Neoadjuvant treatments for locally advanced, resectable esophageal cancer: A network meta-analysis.** *Int J Cancer.* 2018; **143**(2): 430–7. [PubMed Abstract](#) | [Publisher Full Text](#)
32. Al-Batran SE, Hofheinz RD, Pauligk C, *et al.*: **Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial.** *Lancet Oncol.* 2016; **17**(12): 1697–1708. [PubMed Abstract](#) | [Publisher Full Text](#)
33. Noble F, Lloyd MA, Turkington R, *et al.*: **Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.** *Br J Surg.* 2017; **104**(13): 1816–28. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
34. Palmela C, Velho S, Agostinho L, *et al.*: **Body composition as a prognostic factor of neoadjuvant chemotherapy toxicity and outcome in patients with locally advanced gastric cancer.** *J Gastric Cancer.* 2017; **17**(1): 74–87. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
35. Anandavadivelan P, Brismar TB, Nilsson M, *et al.*: **Sarcopenic obesity: A probable risk factor for dose limiting toxicity during neo-adjuvant chemotherapy in oesophageal cancer patients.** *Clin Nutr.* 2016; **35**(3): 724–30. [PubMed Abstract](#) | [Publisher Full Text](#)
36. Awad S, Tan BH, Cui H, *et al.*: **Marked changes in body composition following neoadjuvant chemotherapy for oesophagogastric cancer.** *Clin Nutr.* 2012; **31**(1): 74–7. [PubMed Abstract](#) | [Publisher Full Text](#)
37. Elliott JA, Doyle SL, Murphy CF, *et al.*: **Sarcopenia: Prevalence, and Impact on Operative and Oncologic Outcomes in the Multimodal Management of Locally Advanced Esophageal Cancer.** *Ann Surg.* 2017; **266**(5): 822–30. [PubMed Abstract](#) | [Publisher Full Text](#)
38. Weinheimer EM, Sands LP, Campbellnure WW: **A systematic review of the**

- separate and combined effects of energy restriction and exercise on fat-free mass in middle-aged and older adults: Implications for sarcopenic obesity.** *Nutr Rev.* 2010; **68**(7): 375–88.
[PubMed Abstract](#) | [Publisher Full Text](#)
39. Faithfull S, Turner L, Poole K, *et al.*: **Prehabilitation for adults diagnosed with cancer: A systematic review of long-term physical function, nutrition and patient-reported outcomes.** *Eur J Cancer Care (Engl).* 2019; **28**(4): e13023.
[PubMed Abstract](#) | [Publisher Full Text](#)
 40. Minnella EM, Awasthi R, Loiselle SE, *et al.*: **Effect of Exercise and Nutrition Prehabilitation on Functional Capacity in Esophagogastric Cancer Surgery: A Randomized Clinical Trial.** *JAMA Surg.* 2018; **153**(12): 1081–9.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 41. Prado CM, Purcell SA, Laviano A: **Nutrition interventions to treat low muscle mass in cancer.** *J Cachexia Sarcopenia Muscle.* 2020; **11**(2): 366–80.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 42. Wisnovsky SP, Wilson JJ, Radford RJ, *et al.*: **Targeting mitochondrial DNA with a platinum-based anticancer agent.** *Chem Biol.* 2013; **20**(11): 1323–8.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 43. Fanzani A, Zanola A, Rovetta F, *et al.*: **Cisplatin triggers atrophy of skeletal C2C12 myotubes via impairment of Akt signalling pathway and subsequent increment activity of proteasome and autophagy systems.** *Toxicol Appl Pharmacol.* 2011; **250**(3): 312–21.
[PubMed Abstract](#) | [Publisher Full Text](#)
 44. Damrauer JS, Stadler ME, Acharyya S, *et al.*: **Chemotherapy-induced muscle wasting: association with NF- κ B and cancer cachexia.** *Eur J Transl Myol.* 2008; **18**(2): 7590.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 45. Sorensen JC, Cheregi BD, Timpani CA, *et al.*: **Mitochondria: Inadvertent targets in chemotherapy-induced skeletal muscle toxicity and wasting?** *Cancer Chemother Pharmacol.* 2016; **78**(4): 673–83.
[PubMed Abstract](#) | [Publisher Full Text](#)
 46. Valkenet K, Trappenburg JCA, Gosselink R, *et al.*: **Preoperative inspiratory muscle training to prevent postoperative pulmonary complications in patients undergoing esophageal resection (PREPARE study): Study protocol for a randomized controlled trial.** *Trials.* 2014; **15**: 144.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
 47. Katsura M, Kuriyama A, Takeshima T, *et al.*: **Preoperative inspiratory muscle training for postoperative pulmonary complications in adults undergoing cardiac and major abdominal surgery.** *Cochrane Database Syst Rev.* 2015; (10): CD010356.
[PubMed Abstract](#) | [Publisher Full Text](#)
 48. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/ILSTAD>
 49. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:guYr6WoCrVJhA4/iukRvtw== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/Z0H41K>
 50. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:hxMutBoSr1iC3WtI4SZnQQ== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/RNVIHN>
 51. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/GQTBTM>
 52. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:n3Ypg+unc2oaL7b0oicMng== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/XSJHSZ>
 53. Loughney L: **The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/GTE1QJ>
 54. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/XIXD2L>
 55. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:55wftwI8vr7Hy9dqO6kexA== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/BAHW00>
 56. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/LOB8PG>
 57. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** <https://doi.org/10.7910/DVN/LOB8PG>, Harvard Dataverse, DRAFT VERSION". Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/DSCSOI>
 58. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** <https://doi.org/10.7910/DVN/DSCSOI>. Harvard Dataverse, V1, UNF:6:1Rq6HGus1b8Tb9ajhg/w0w== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/ZDR7C1>
 59. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:1Rq6HGus1b8Tb9ajhg/w0w== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/AGC3IL>
 60. Loughney L: **Replication Data for: The effects of cancer therapies on physical fitness before oesophagogastric cancer surgery: A prospective, blinded, multi-centre, observational, cohort study.** Harvard Dataverse, V1, UNF:6:ww4HfKTjEaoYQGkyApHnIQ== [fileUNF], 2021.
<http://www.doi.org/10.7910/DVN/IM11CG>
 61. Loughney L: **STROBE Checklist.** Harvard Dataverse, V1, 2021.
<http://www.doi.org/10.7910/DVN/NUV1OI>

Open Peer Review

Current Peer Review Status:

Version 1

Reviewer Report 18 August 2021

<https://doi.org/10.3310/nihropenres.14333.r28397>

© 2021 Hussey J. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Juliette Hussey

Discipline of Physiotherapy, School of Medicine, Trinity College Dublin, Dublin, Ireland

This is an excellent study which is very clearly presented. I thought the question was clearly defined. The methods are clear and the data analysis appropriate. I could not find any major limitations.

The paper will add to the scientific research in the area. This is an area of growth and understanding how to improve cardiorespiratory fitness in this cohort is gaining interest.

The authors are to be commended.

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Exercise in cancer survivorship

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Reviewer Report 02 July 2021

<https://doi.org/10.3310/nihropenres.14333.r28396>

© 2021 Sultan J et al. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Javed Sultan

Department of Oesophagogastric Surgery, Salford Royal Foundation Trust, Salford, UK

Patrick Casey

University of Manchester, Manchester, UK

Thank you for the opportunity to review this manuscript produced by leaders in this field.

The group aimed to validate the hypothesis that neoadjuvant chemoradiotherapy impacted on the physical fitness (defined as VO_2 peak and at AT) of patients with OG cancer. Furthermore, the impact this had on post-operative outcomes and overall survival was also examined. The group clearly demonstrate that most patients become less fit although only one third of patient move risk strata. To this end, the group have fulfilled their primary aim. However, this decline in fitness was not associated with worse survival at 1 and 5 years which, in this relatively small underpowered and self selecting group, is not surprising.

We congratulate the authors on being able to blind the treating team to the CPET result: a clinically significant piece of information which any surgeon or anaesthetist would be keen to have. I assume this was subject to ethical consideration and cleared.

The unstandardised chemoradiotherapy regimes is pragmatically understandable but may undermine the results; which the group rightfully highlight as a limitation. We assume the group will also look at the impact of FLOT chemotherapy which is now gold-standard but notably not reported in this study at all.

Whilst 1 and 5 year survival did not appear different between the comparison groups the fact that only 46% of patients in the high risk group were discharged to their own home and had a much higher re-admission rate is a significant, patient-centred, outcome which in our opinion should be emphasised.

A single grammatical point noted:

In the eligibility criteria paragraph - is the line "*Eligible patients were staged according to a pre-determined protocol*" essentially repeated?

Is the work clearly and accurately presented and does it cite the current literature?

Yes

Is the study design appropriate and is the work technically sound?

Yes

Are sufficient details of methods and analysis provided to allow replication by others?

Yes

If applicable, is the statistical analysis and its interpretation appropriate?

Yes

Are all the source data underlying the results available to ensure full reproducibility?

Yes

Are the conclusions drawn adequately supported by the results?

Yes

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Oesophagogastric cancer outcomes with regard to preoperative fitness, rehabilitation and muscle mass.

We confirm that we have read this submission and believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.